A Phase I Dose Escalation Study of Concurrent Low Dose Radiation With Sorafenib in Three Anatomically-based Independent Cohorts (Thorax, Abdomen, Pelvis)
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To measure safety and maximum tolerated dose, all adverse events will be assessed in line with dose limiting toxicities.
Outcome is measured prior to each dose escalation.
Princess Margaret Hospital, Canada
Canada: Health Canada